Boundless Bio, Inc.
BOLDNasdaq
$2.48
↓ -0.4%Jul 17 close · end-of-day
Price
1Y↑ +117.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$55.6M
Enterprise Value
-$37.3M
P/E
—
P/S
—
P/B
0.6
EV/EBITDA
—
PEG
—
FCF Yield
-85.7%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$56.0M
Free Cash Flow (TTM)
-$47.6M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-64.8%
ROIC
—
Debt / Equity
—
Net Cash
$92.8M
Return 1Y
+110.2%
Company profile
We are a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. We were originally founded as a Delaware corporation on April 10, 2018 under the name Pretzel Therapeutics, Inc. On July 8, 2019, we changed our name to Boundless Bio, Inc. Our principal executive offices are located at 9880 Campus Point Drive, Suite 120, San Diego, CA.
- CEO
- Zachary D. Hornby
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- California
- Website
- boundlessbio.com
Earnings
BOLD Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.60↓ -15.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$54.8M | -$73.3M | -$63.6M |
| Net income | -$49.4M | -$65.4M | -$58.2M |
| Diluted EPS | -$40.65 | -$3.85 | -$2.60 |
| Operating cash flow | -$46.9M | -$60.8M | -$46.7M |
| Free cash flow | -$47.5M | -$63.4M | -$47.2M |
| Gross margin | — | — | — |
| Operating margin | — | — | — |
| Net margin | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$19.4M | -$18.7M | -$18.3M | -$17.3M | -$17.1M | -$15.1M | -$14.0M | -$14.5M |
| Net income | -$17.0M | -$16.5M | -$16.4M | -$15.8M | -$15.7M | -$13.9M | -$12.9M | -$13.6M |
| Diluted EPS | -$0.77 | -$0.74 | $9.93 | -$0.71 | -$0.70 | -$0.62 | -$0.57 | -$0.60 |
| Operating cash flow | -$16.2M | -$13.3M | -$15.6M | -$14.5M | -$11.8M | -$10.2M | -$10.1M | -$15.0M |
| Free cash flow | -$17.7M | -$13.7M | -$16.0M | -$14.6M | -$11.9M | -$10.2M | -$10.5M | -$15.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 23, 2026
- 27d agoSector Update: Healthcare Stocks Higher Late Afternoonfinance.yahoo.com
- 27d agoSector Update: Healthcare Stocks Advance in Afternoon Tradingfinance.yahoo.com
- 27d agoBOLD Stock Is Up 90% — Here's What's Behind The Biggest Rally In Company Historystocktwits.com
- 27d agoBoundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placementfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-16 | TANG KEVIN C | Buy | 18,491 | $2.44 | $45,118.04 | filing |
| 2026-07-15 | TANG KEVIN C | Buy | 1,600 | $2.44 | $3,904.00 | filing |
| 2026-07-14 | TANG KEVIN C | Buy | 43,878 | $2.43 | $106,623.54 | filing |
| 2026-07-13 | TANG KEVIN C | Buy | 48,211 | $2.42 | $116,670.62 | filing |
| 2026-07-10 | TANG KEVIN C | Buy | 43,367 | $2.43 | $105,381.81 | filing |
| 2026-07-09 | TANG KEVIN C | Buy | 7 | $2.48 | $17.36 | filing |
| 2026-07-08 | TANG KEVIN C | Buy | 14,338 | $2.46 | $35,271.48 | filing |
| 2026-07-07 | TANG KEVIN C | Buy | 15,810 | $2.48 | $39,208.80 | filing |
| 2026-07-06 | TANG KEVIN C | Buy | 27,062 | $2.49 | $67,384.38 | filing |
| 2026-07-02 | TANG KEVIN C | Buy | 9,821 | $2.49 | $24,454.29 | filing |
| 2026-07-01 | TANG KEVIN C | Buy | 71,612 | $2.49 | $178,313.88 | filing |
| 2026-07-01 | CRANDELL KEITH | Sale | 16,000 | $2.49 | $39,840.00 | filing |
| 2026-07-01 | ARCH Venture Fund IX, L.P. | Sale | 16,000 | $2.49 | $39,840.00 | filing |
| 2026-07-01 | ARCH Venture Fund IX, L.P. | Option exercise | 16,000 | $1.03 | $16,480.00 | filing |
| 2026-07-01 | CRANDELL KEITH | Option exercise | 16,000 | $1.03 | $16,480.00 | filing |
| 2026-06-30 | TANG KEVIN C | Buy | 25,930 | $2.54 | $65,862.20 | filing |
| 2026-06-30 | TANG KEVIN C | Buy | 100 | $2.50 | $250.00 | filing |
| 2026-06-29 | TANG KEVIN C | Buy | 63,985 | $2.47 | $158,042.95 | filing |
| 2026-06-29 | TANG KEVIN C | Buy | 777 | $2.48 | $1,926.96 | filing |
| 2026-06-26 | TANG KEVIN C | Buy | 75,047 | $2.55 | $191,369.85 | filing |
| 2026-06-26 | TANG KEVIN C | Buy | 134 | $2.54 | $340.36 | filing |
| 2026-06-25 | TANG KEVIN C | Buy | 145,880 | $2.48 | $361,782.40 | filing |
| 2026-06-25 | TANG KEVIN C | Buy | 510 | $2.56 | $1,305.60 | filing |
Latest 23 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.